xx, x-x
Gen. Physiol. Biophys. (2019), 38,
xx–xx
doi: 10.4149/gpb_2018047
Synergic effects of inhibition of glycolysis and multikinase receptor
signalling on proliferation and migration of endothelial cells
Jana Horváthová1, Roman Moravčík1, Andrej Boháč2,3 and Michal Zeman1
1 Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University in Bratislava, Brati-
OF
slava, Slovakia
RO
2 Department of Organic Chemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
3 Biomagi, Ltd., Bratislava, Slovakia
RR
EC
TE
DP
Abstract. Activated endothelial cells play a crucial role in the formation of new blood vessels,
a process known as angiogenesis, which can underlie the development of several diseases. Different
antiangiogenic therapies aimed against vascular endothelial growth factor (VEGF), the dominant
pro-angiogenic cytokine, have been developed. Because the treatment is limited in its efficiency and
has side effects, new approaches are currently being evaluated. One of them is aimed at blocking
glycolysis, the dominant energetic pathway of activated endothelial cells during vessel sprouting.
In the present study we investigated the efficiency of a combined strategy to inhibit glycolysis and
block VEGF action on proliferation and migration in human endothelial cells. Human endothelial
cells (HUVECs) were treated with different doses of the glycolysis inhibitor 3-(3-pyridinyl)-1(4-pyridinyl)-2-propen-1-one (3PO) in combination with the multikinase inhibitor sunitinib
l-malate. Our results show that HUVECs with reduced glycolytic activity are more sensitive to
co-administered sunitinib. Analysis of post-receptor pathways controlling proliferation and migration of HUVECs showed suppression of phosphorylated PI3K/Akt and ERK1/2 after exposure to
sunitinib but not to 3PO in 10 µM concentration. Our results suggest that simultaneous inhibition
of energy metabolism and blocking of pro-angiogenic growth factor signalling pathways can be
a promising strategy to inhibit the pathological form of angiogenesis.
CO
Key words: Metabolism — Angiogenesis — Endothelial cells — 3PO — Sunitinib
Introduction
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
1
Angiogenesis, the process of creating new blood vessels from
pre-existing structures, is involved in many physiological and
pathological processes (Carmeliet and Jain 2011). Angiogenesis is a highly coordinated process: upon induction of
sprouting by pro-angiogenic growth factors, such as vascular
endothelial growth factor (VEGF), quiescent endothelial
cells become active and increase their level of glycolysis.
Subsequently, the cells begin to proliferate, migrate and form
new vessels (De Bock et al. 2013).
Correspondence to: Roman Moravčík, Department of Animal
Physiology and Ethology, Faculty of Natural Sciences, Comenius
University in Bratislava, Mlynská dolina, Ilkovičova 6, 842 15
Bratislava, Slovakia
E-mail: roman.moravcik@uniba.sk
The majority of ATP generated by endothelial cells for
proliferation and migration is obtained from glycolysis
(Xu et al. 2014). Despite the fact that endothelial cells are
exposed to a high concentration of oxygen in circulating
blood, they prefer glycolysis over oxidative phosphorylation (Gatenby and Gillies 2004). There are several reasons
why endothelial cells favour glycolysis: 1) the consumption of oxygen by endothelial cells is not so high, enabling
oxygen to diffuse to the surrounding tissues (Verdegem et
al. 2014); 2) endothelial cells are exposed to lower levels
of reactive oxygen species, so they are partially protected
from oxidative stress; 3) endothelial cells can also migrate
under conditions of hypoxia and are able to use glycolysis
to form new vessels under hypoxic conditions (Mertens et
al. 1990); 4) although ATP production per mole of glucose
in oxidative phosphorylation is higher, ATP production in
glycolysis is faster. The production of ATP during glycolysis
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Horváthová et al.
2
OF
intracellular pathways are predominantly affected and might
be targets for development of new inhibitors with higher efficiency and lower side effects when co-administered with
glycolysis inhibitors. In our recent study (Murár et al. 2018)
we proposed that 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen1-one (3PO) could be a multi-targeted inhibitor; therefore,
the additional aim of the present study was to explore if it
directly interacts with pathways controlling proliferation and
migration of HUVECs.
Material and Methods
RO
Human umbilical vein endothelial cells (HUVECs) were cultured in endothelial cell growth medium (ECGM; PromoCell,
Germany), containing endothelial cell growth supplements
(ECGS; PromoCell) and were maintained at 37°C in humidified incubator (Heal Force Bio-meditech, China) containing
5% CO2. Cells were used between passages 1–6. HUVECs
were isolated from fresh umbilical cords digested by collagenase. The umbilical vein was cannulated and rinsed with
Earle’s Balanced Salt Solution (EBSS). The rinsed vein was
filled with 5 ml of collagenase NB4 (7 mg/ml) (Serva, Germany) dissolved in EBSS. After incubation for 20 min at 37°C
cells were washed from the vein with Hank’s Balanced Salt
Solution (HBSS) and the suspension was spin at 300 × g for
15 minutes. Subsequently HUVECs were cultured in ECGM
supplemented with ECGS and antibiotics (Biosera, France).
CO
RR
EC
TE
DP
is comparable with oxidative phosphorylation as far as there
is a sufficient amount of glucose, which is always present
in circulating blood (Vander Heiden et al. 2009); 5) side
branches of glycolysis are important for the biosynthesis of
macromolecules (Leopold et al. 2003).
Antiangiogenic therapy is one of the supplementary strategies for cancer treatment and is aimed at inhibition of angiogenic signals, such as VEGF, leading to destruction of the
vasculature and starving of the tumour (Gatenby and Gillies
2004). Inhibition of VEGF signalling using antibodies against
VEGF (Ferrara et al. 2004) or VEGF receptor antagonists
(Shaheen et al. 2001) proved its potent antiangiogenic effects.
The first approved angiogenesis inhibitor was the humanized monoclonal VEGF-antibody Bevacizumab (Avastin,
Pfizer). Bevacizumab binds VEGF and inhibits its interaction
with the VEGF receptor, thus preventing cell proliferation
and migration (Herbst et al. 2005). In addition to VEGF
receptors, other tyrosine kinase receptors (platelet-derived
growth factor receptor and fibroblast growth factor receptor) have important roles in tumour progression and blood
vessel formation (Kerbel and Folkman 2002). Simultaneous
blocking of several growth factors by multitargeted tyrosine
kinase inhibitor sunitinib l-malate was shown as a potent
antitumor and anti-angiogenic strategy (Mendel et al. 2003).
Blocking of VEGF has become a clinically attractive strategy, since it interferes with different cell control pathways.
Activation of tyrosine kinase receptors leads to up-regulation
of several post-receptor pathways, including the Ras/Raf/
MEK/ERK1/2, which regulates proliferation and migration
of endothelial cells (Gotink and Verheul 2010). Moreover,
phosphatidylinositol 3´-kinase (PI3K) and its downstream
activated serine/threonine kinase Akt/protein kinase
B (PKB) are associated with several processes involved in
angiogenesis control. This pathway includes endothelial cell
migration, proliferation and survival (Engelman et al. 2006).
However, both insufficient efficacy and the development of
resistance limit the clinical use of VEGF-blocking therapy.
Increased levels of glycolysis during proliferation and
migration of endothelial cells point to glycolysis as another
attractive therapeutic target for the inhibition of angiogenesis
(De Bock et al. 2013). Silencing in vitro or inactivation in
vivo of the key glycolytic enzyme phosphofructokinase-2/
fructose-2,6-bisphosphatase-3 (PFKFB3) reduced the formation of new vessels (De Bock et al. 2013, Schoors et al. 2014).
The aim of our study was to explore the effects of simultaneous inhibition of glycolysis as the dominant metabolic
pathway in activated endothelial cells together with inhibition of post-receptor signal cascades by the multiple-kinase
inhibitor sunitinib. We hypothesized that such combined
treatment can have a synergic inhibitory effect on the proliferation and migration of endothelial cells. Moreover, we
analysed post-receptor signal pathways that mediated proliferation and survival of endothelial cells to identify which
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
Drug preparation
Stocks solutions of tyrosine kinase receptors inhibitor sunitinib l-malate (Pfizer, USA) and glucose metabolism inhibitor 3PO, synthetized as described in Murár et al. (2018), were
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich,
USA) in a concentration of 10 mM. Subsequently, stock
solutions were diluted in ECGM to required concentration.
All inhibitors were used at concentration, which induced
no cytotoxicity.
Cell proliferation assay
HUVECs were seeded in a 96-well plate at a density 5 × 103
cells/well. After the cells reached 80% confluence, the medium was removed, and the cells were treated with different
doses of inhibitors. Cells were incubated in the absence
(control) or in the presence of inhibitors for 24 hours. Cell
proliferation was performed by the MTT assay (SigmaAldrich) according to the manufacturer’s instructions. The
absorbance was measured at a wavelength of 590 nm (Elisa
reader Elx800 TM; Bio-Tek Instruments, USA). Proliferation
was evaluated as the percentage of absorbance of the samples
treated with different doses of inhibitors compared with
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Inhibition of endothelial cell metabolism
DP
Cells were seeded in 24-well plates coated with 1.5% gelatine
(Sigma-Aldrich) at a density 5 × 105 cells/well. After reaching a confluent monolayer, the medium was replaced with
starvation medium, and the cells were incubated for further
17 hours. Each well was wounded using the tip of a pipette.
Subsequently, the cells were incubated in starvation medium
containing 20 ng/ml of VEGF165 (Peprotech, USA) in the
presence or absence of inhibitors for 8 hours. Migration of
HUVECs was observed with an Olympus IMT2 inverted
optical microscope (Olympus, Japan) and recorded by
a Moticam 1000 camera system (Motic Incorporation, Hong
Kong) at time zero and 8 hours after treatment. Changes in
cell migration were evaluated by using the software Motic
Images 2.0 ML (Motic incorporation).
OF
Migration assay
choninic acid assay (BCA assay kit; Sigma-Aldrich). Equal
amounts of protein were separated by SDS-PAGE (Owl
P8DS; Owl Separation systems, USA) and transferred to
a nitrocellulose membrane (Thermo Scientific, Germany).
The membrane was blocked for 1 hour at room temperature using bovine serum albumin (BSA; Serva) to prevent
nonspecific binding of antibodies. Afterwards, blots were
incubated with anti-Akt, anti-phospho-Akt, anti-p 44/42
MAPK (ERK1/2) and anti-phospo-p 44/42 MAPK (ERK1/2)
antibodies followed by incubation with goat anti-rabbit
HRP and horse anti-mouse HRP secondary antibodies (all
antibodies were obtained from Cell Signaling Technology,
USA) at concentrations which were previously tested. For
protein visualization, the ECL Substrate ClarityTM (BioRad,
USA) was used. The ratio of phosphorylated to total forms
of protein was determined using the software Image Studio
Lite Ver. 5.2 (Li Cor, USA).
RO
untreated controls (A590 treated/A590 untreated × 100). Data
are presented as the mean ± standard error of the mean.
Immunoblotting
Results are expressed as mean ± standard error of the mean
(SEM). Statistical analyses were performed using STATISTICA 7.0 (StatSoft Inc.). Data were analysed by one-way
ANOVA followed by a Tukey post hoc test. The value p <
0.05 was considered as significant.
Results
Effect of sunitinib and 3PO on cell migration
Cell migration ability was quantified after treatment with
3PO and sunitinib alone or in combination (Figure 1). Suni-
CO
RR
EC
TE
For Western blot analysis, HUVECs were used at passage
1–2. Cells were cultured in 6-well plates at a density of 1.2 ×
105 cells/well until they reached 80% confluence. Subsequently, cells were pre-incubated with medium containing
the inhibitor 3PO at two different concentrations (10 and
20 µM) for 24 hours. Then, the medium was removed, and
cells were incubated with different doses of 3PO and sunitinib for 1 hour. Afterwards, 2 µl of VEGF165 were added to
each well (stock solution of VEGF165 10 ng/µl; Peprotech).
Following treatment, cells were lysed in a lysis buffer. The
total protein concentration was determined using the bicin-
Statistical analysis
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
3
Figure 1. Inhibitory effect of sunitinib and 3PO on cell migration. Confluent cell monolayers were wounded, and endothelial cells were
treated with vehicle (control), different concentrations of sunitinib and 3PO at 10 µM (A) and 20 µM (B). The wounded areas were
photographed at the beginning and after 8 hours of incubation with inhibitors. Graphs represent the mean percentage of recovered areas
± SEM from three different experiments. + p < 0.05 combined effect of sunitinib + 3PO compared to 0.1 and 1 µM sunitinib; +++ p < 0.001
combined effect of sunitinib + 3PO compared to sunitinib at 0.1–10 µM; *** p < 0.001 combined effect of sunitinib + 3PO compared to
3PO at 10 µM or 20 µM.
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Horváthová et al.
4
Effect of 3PO and sunitinib on Akt and ERK1/2
phosphorylation
RO
OF
Changes in VEGF-induced phosphorylation of the PI3K/Akt
and ERK1/2 signalling pathways were evaluated by Western
blot analysis after treatment with sunitinib in the concentration range from 0.1 to 10 µM and 3PO at 10 and 20 µM
administered alone or in combination. Inhibitors applied
individually decreased VEGF-induced phosphorylation of
protein kinase PI3K/Akt and ERK1/2 in a dose-dependent
manner except 3PO at 10 µM. Simultaneous administration
of 3PO at 10 µM and sunitinib in the range of 0.1–10 µM
reduced phosphorylation of ERK1/2 (Figure 3A) and PI3K/
Akt (Figure 3C). Interestingly, the combined effect of the two
compounds did not decrease phosphorylation of PI3K/Akt
and ERK1/2 compared with inhibitors applied individually
(Figure 3). The inhibitor 3PO at 20 µM showed stronger negative effects on phosphorylation of PI3K/Akt and ERK1/2 after
VEGF-induced phosphorylation (Figure 3B, 3D). Simultaneous treatment with sunitinib in the concentration range of
0.1–10 µM dose-dependently decreased phosphorylation of
PI3K/Akt and ERK1/2 compared with the total protein form.
DP
tinib at 0.1 µM had no effect, but higher doses decreased cell
migration compared to control cells incubated in starvation
medium supplemented with VEGF. At 20 µM, 3PO reduced
cell migration (Figure 1B), but a lower concentration of 3PO
had no effect on recovery of wounded areas (Figure 1A).
The combined action of 3PO with sunitinib in lower concentrations (1 µM) more efficiently inhibited cell migration
in comparison with 3PO or sunitinib alone (Figure 1A). In
contrast, the combined effect of 3PO and sunitinib at a higher
concentration (10 µM) did not exhibit a synergistic inhibitory effect on cell migration compared to sunitinib alone.
Interestingly, lower concentrations of sunitinib (0.1–1 µM) in
combination with 3PO at 10 µM reduced cell migration into
wounded areas. Simultaneous administration of sunitinib
at 0.1–10 µM with 3PO at 20 µM significantly decreased
HUVEC cell migration compared with inhibitors applied
alone (Figure 1B).
Effect of sunitinib and 3PO on cell proliferation
CO
RR
EC
TE
Effects of both inhibitors on cell proliferation were assayed
with 3PO at 10 or 20 µM and different concentrations of
sunitinib. Treatment with 3PO at 10 µM did not affect cell
proliferation (Figure 2A), whereas the higher dose of 3PO
reduced cell proliferation (Figure 2B).
Treatment of cells with 3PO at 10 µM and sunitinib at
0.1–1 µM did not induce changes in cell proliferation, but the
combined action of sunitinib and 3PO at 10 µM substantially
decreased cell proliferation in comparison with cells treated
with inhibitors applied individually (Figure 2A).
Administration of 3PO at 20 µM and sunitinib in the
range of 0.1–10 µM negatively affected cell proliferation
compared to the inhibitory effect of sunitinib or 3PO applied
alone (Figure 2B).
Discussion
In the present study, we explored the possibility of inhibiting pathological angiogenesis via suppression of glucose
metabolism and blocking of growth factor receptors, either
individually or simultaneously, as a novel antiangiogenic and
cancer treatment strategy.
The inhibitory effect of 3PO on proliferation and migration in HUVEC cells was dose-dependent. Cells incubated
in the presence of lower 3PO concentrations (≤10 µM) did
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
Figure 2. Inhibitory effect of sunitinib and 3PO on cell proliferation. After reaching confluent monolayer endothelial cells were treated
with vehicle (control), 3PO at 10 µM (A) and 20 µM (B) and different doses of sunitinib for 24 hours. Changes in cell proliferation were
evaluated after 4 hours of incubation with MTT. Data represent the mean ± SEM of three independent experiments. + p < 0.05 combined
effect of sunitinib + 3PO compared to 10 µM sunitinib; *** p < 0.001 combined effect of sunitinib + 3PO compared to 3PO at 10 µM or
20 µM; +++ p < 0.001 combined effect of sunitinib + 3PO compared to sunitinib at 0.1–10 µM.
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Inhibition of endothelial cell metabolism
OF
RO
DP
TE
EC
RR
CO
Figure 3. Quantification of PI3K/Akt and ERK1/2 phosphorylation after treatment with different doses of 3PO and sunitinib administered
alone or in combination. The ratio between phosphorylated and total forms of PI3K/Akt (A, B) was evaluated as the mean percentage
of groups ± SEM (n = 3). Western blots illustrating density of phosphorylated form compared with total form of Akt are shown below
the graph. The ratio between phosphorylated and total forms of ERK1/2 (C, D) was evaluated as the mean percentage of groups ± SEM
(n = 3). Western blots illustrating density of phosphorylated form compared to total form of ERK1/2 are shown below the graph. ** p <
0.01, *** p < 0.001 combined effect of sunitinib + 3PO compared to 3PO.
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
5
not show any morphological changes, and cell proliferation
and migration were not suppressed. However, 3PO at a concentration of 20 µM efficiently inhibited cell migration, and
the inhibitory effect was much more pronounced in comparison with 10 µM. Our data are in accordance with previous studies. The inhibitor 3PO in the concentration range
of 15–20 µM led to a reduction of glycolysis in endothelial
cells, resulting in decreased proliferation and migration
(Schoors et al. 2014). Moreover, blockade of glycolysis by
3PO reduced vessel sprouting in zebra fish embryos by
inhibiting endothelial cell proliferation and migration (De
Bock et al. 2013). In our recent study (Murár et al. 2018),
in which cell proliferation was estimated on the basis of
bromodeoxyuridine incorporation into newly synthetized
DNA in living cells, the inhibitory effects were observed
even with lower doses of 3PO, probably reflecting the higher
sensitivity of the assay in comparison with the MTT test.
The importance of glycolysis for energy metabolism of
endothelial cells was documented in several previous studies (Clem et al. 2008; De Bock et al. 2013). The complete
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Horváthová et al.
6
a strategy enables decreasing the doses of administered drugs
and affects cells which are resistant to a single treatment.
Signalling pathway
RO
OF
Activation of the protein kinases PI3K/Akt and ERK1/2 is
necessary for regulation of cell proliferation and migration.
In line with previously published data, our results showed
that sunitinib significantly inhibited the phosphorylation of
p-Akt and p-ERK1/2 in human endothelial cells (Moravčík et
al. 2016). Moreover, our recent study (Murár et al. 2018) suggested that 3PO may inhibit other important biological targets
in addition to PFKFB3. Therefore, we explored whether the
simultaneous action of sunitinib and 3PO is mediated through
the inhibition of phosphorylation of protein kinases PI3K/Akt
and ERK1/2. Although sunitinib dose-dependently inhibited
phosphorylation of protein kinase PI3K/Akt and ERK1/2, the
simultaneous actions of both inhibitors did not always amplify
the inhibitory effects on phosphorylation in comparison with
the inhibitor applied individually. A similar stimulatory effect
was observed in cancer cells. The selective tyrosine kinase
inhibitor sorafenib applied at low concentrations (<1 µM)
increased human bladder cancer cell proliferation and migration, which could be mediated through activation of the
ERK1/2 signalling pathway (Rose et al. 2010).
Since simultaneous treatment with sunitinib and 3PO did
not result in additional inhibition of PI3K/Akt and ERK1/2
phosphorylation, the effects of 3PO are not mediated via
RISK pathways. Therefore, additional possibilities and other
signalling pathways must be considered in future studies. In
summary, our study confirmed the dose-dependent inhibitory
effects of the glycolytic inhibitor 3PO and the multikinase
inhibitor sunitinib on the migration and proliferation of endothelial cells. Simultaneous treatment with both inhibitors
resulted in almost all cases a more pronounced decrease in cell
migration and proliferation in comparison with individually
administered drugs. Molecular data suggest that the higher
efficiency of combined administration of these two inhibitors is not mediated by additional up-regulation of the PI3K/
Akt and ERK1/2 signalling pathways, which are involved in
the control of migration and proliferation of HUVECs. Our
results indicate a novel strategy for inhibition of cell migration
and proliferation with future prospects for cancer treatment.
CO
RR
EC
TE
DP
inhibition of glycolysis using glycolysis inhibitors, such as
2-deoxy-D-glucose, results in cell death. However, blockade
of the key glycolytic enzyme PFKFB3 leads to a reduction of
vessel sprouting, while the cells remain alive (De Bock et al.
2013). The inhibitor 3PO lowers the activity of PFKFB3 and
subsequently reduces glycolysis, resulting in suppression of
endothelial cell growth (Clem et al. 2008; Murár et al. 2018).
Our results proved the expected inhibitory effects of
sunitinib on endothelial cell migration and proliferation.
Sunitinib administered in concentrations from 0.1 to 10 µM
dose-dependently decreased the proliferation and migration
of endothelial cells. These effects are in line with previously
published data on endothelial and cancer cells (Mendel et al.
2003; Pla et al. 2014), as well as the clinical use of sunitinib
in the treatment of solid cancers (Socinski et al. 2008).
In the present study, we explored if the simultaneous
inhibition of glucose metabolism and growth factor receptor signalling has synergistic effects, is more efficient and
enables the administered doses of both drugs to be decreased
for clinical use. Indeed, we found that treatment with 3PO
and sunitinib in combination resulted in more pronounced
inhibition of HUVEC migration and proliferation, and the
effect was enhanced when a higher dose of 3PO was administered. Our experiments demonstrated that the inhibitory
effect of multikinase inhibitor sunitinib may be amplified
by simultaneous inhibition of glycolysis. Endothelial cells
treated with different doses of sunitinib in combination with
3PO (20 µM) significantly decreased their migration and
proliferation. Several animal studies support the possibility
that the simultaneous inhibition of growth factor receptors and glucose metabolism has the potential to be a new
antiangiogenic strategy. Treatment of zebrafish embryos
with 3PO and sunitinib at different doses resulted in vessel
defects, suggesting that PFKFB3 blockade can enhance the
antiangiogenic effect of VEGFR inhibition (Schoors et al.
2014). Moreover, potent anti-angiogenic efficacy was demonstrated for another multikinase inhibitor, nintedanib, in
combination with the glycolysis inhibitor 3PO in a mouse
model of breast cancer (Pisarsky et al. 2016).
From a translational point of view, it is important that
cancer cells exhibit similar metabolic characteristics as activated endothelial cells and use predominantly glycolysis
for their metabolism. Inhibition of the glycolytic enzyme
PFKFB3 in cancer cells is responsible for decreased proliferation and migration (Conradi et al. 2017). A low dose of 3PO
(25 mg/kg) reduced the level of glycolysis by 15–20%, caused
tumour necrosis, negatively influenced cancer cell invasion,
and induced normalization of tumour vessels. A high dose
of 3PO (70 mg/kg) substantially impaired proliferation of
cancer cells and subsequently increased cell death. Therefore,
the combined inhibition of glycolysis and growth factor
receptors can inhibit both cancer and activated endothelial
cells and more efficiently inhibit tumour progression. Such
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
Acknowledgements. This project was supported by
grants VEGA 1/0670/18, 1/0557/18 and APVV-16-0209.
We are grateful to Pfizer Inc. for a gift of sunitinib l-malate.
References
Carmeliet P, Jain RK (2011): Molecular mechanisms and clinical
applications of angiogenesis. Nature 473, 298–307
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
Inhibition of endothelial cell metabolism
RO
OF
developed tyrosine kinase inhibitor in comparison with sunitinib. Gen. Physiol. Biophys. 35, 511–514
https://doi.org/10.4149/gpb_2015055
Murár M, Horvathová J, Moravčík R, Addová G, Zeman M, Boháč
A (2018): Synthesis of glycolysis inhibitor (E)-3-(pyridin-3yl)-1-(pyridin-4-yl)prop-2-en-1-one (3PO) and its inhibition
of HUVEC proliferation alone or in a combination with the
multi-kinase inhibitor sunitinib. Chem. Pap. 72, 2979–2985
https://doi.org/10.1007/s11696-018-0548-x
Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J,
Hess C, Christofori G (2016): Targeting metabolic symbiosis to
overcome resistance to anti-angiogenic therapy. Cell Rep. 15,
1161–1174
https://doi.org/10.1016/j.celrep.2016.04.028
Pla AF, Brossa A, Bernardini M, Genova T, Grolez G, Villers A,
Leroy X, Prevarskaya N, Gkika D, Bussolati B (2014): Differential sensitivity of prostate tumor derived endothelial cells to
sorafenib and sunitinib. BMC Cancer 14, 939
https://doi.org/10.1186/1471-2407-14-939
Rose A, Grandoch M, vom Dorp F, Rübben H, Rosenkranz A,
Fischer J, Weber AA (2010): Stimulatory effects of the multi‐
kinase inhibitor sorafenib on human bladder cancer cells. Br.
J. Pharmacol. 160, 1690–1698
https://doi.org/10.1111/j.1476-5381.2010.00838.x
Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière
B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A,
Goveia J (2014): Partial and transient reduction of glycolysis
by PFKFB3 blockade reduces pathological angiogenesis. Cell
Metab. 19, 37–48
https://doi.org/10.1016/j.cmet.2013.11.008
Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas
R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE (2001):
Tyrosine kinase inhibition of multiple angiogenic growth factor
receptors improves survival in mice bearing colon cancer liver
metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61, 1464–1468
Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani
ChP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al.
(2008): Multicenter, Phase II trial of sunitinib in previously treated,
advanced non-small-cell lung cancer. J. Clin. Oncol. 26, 650–656
https://doi.org/10.1200/JCO.2007.13.9303
Vander Heiden MG, Cantley LC, Thompson CB (2009): Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science 324, 1029–1033
https://doi.org/10.1126/science.1160809
Verdegem D, Moens S, Stapor P, Carmeliet P (2014): Endothelial
cell metabolism: parallels and divergences with cancer cell
metabolism. Cancer Metab. 2, 19
https://doi.org/10.1186/2049-3002-2-19
Xu Y, An X, Guo X, Habtetsion TG, Wang Y, Xu X, Kandala S, Li Q,
Li H, Zhang C (2014): Endothelial 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase, isoform 3 plays a critical role in
angiogenesis. Arterioscler. Thromb. Vasc. Biol. 34, 1231–1239
https://doi.org/10.1161/ATVBAHA.113.303041
CO
RR
EC
TE
DP
https://doi.org/10.1038/nature10144
Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku
MA, Arumugam S, Dean WL, Eaton J (2008): Small-molecule
inhibition of 6-phosphofructo-2-kinase activity suppresses
glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110–120
https://doi.org/10.1158/1535-7163.MCT-07-0482
Conradi L-C, Brajic A, Cantelmo AR, Bouché A, Kalucka J, Pircher
A, Brüning U, Teuwen L-A, Vinckier S, Ghesquière B (2017):
Tumor vessel disintegration by maximum tolerable PFKFB3
blockade. Angiogenesis 20, 599–613
https://doi.org/10.1007/s10456-017-9573-6
De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW,
Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs
S, Eelen G (2013): Role of PFKFB3-driven glycolysis in vessel
sprouting. Cell 154, 651–663
https://doi.org/10.1016/j.cell.2013.06.037
Engelman JA, Luo J, Cantley LC (2006): The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
Nat. Rev. Genet. 7, 606–619
https://doi.org/10.1038/nrg1879
Ferrara N, Hillan KJ, Gerber H-P, Novotny W (2004): Discovery
and development of bevacizumab, an anti-VEGF antibody for
treating cancer. Nat. Rev. Drug Discov. 3, 391–400
https://doi.org/10.1038/nrd1381
Gatenby RA, Gillies RJ (2004): Why do cancers have high aerobic
glycolysis? Nat. Rev. Cancer 4, 891–899
https://doi.org/10.1038/nrc1478
Gotink KJ, Verheul HM (2010): Anti-angiogenic tyrosine kinase
inhibitors: what is their mechanism of action? Angiogenesis
13, 1–14
https://doi.org/10.1007/s10456-009-9160-6
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T,
Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, et al.
(2005): Phase I/II trial evaluating the anti-vascular endothelial
growth factor monoclonal antibody bevacizumab in combination with HER-1/epidermal growth factor receptor tyrosine
kinase inhibitor erlotinib for patients with recurrent non-smallcell lung cancer. J. Clin. Oncol. 23, 2544–2555
https://doi.org/10.1200/JCO.2005.02.477
Kerbel R, Folkman J (2002): Clinical translation of angiogenesis
inhibitors. Nat. Rev. Cancer 2, 727–739
https://doi.org/10.1038/nrc905
Leopold JA, Walker J, Scribner AW, Voetsch B, Zhang Y-Y, Loscalzo AJ, Stanton RC, Loscalzo J (2003): Glucose-6-phosphate
dehydrogenase modulates vascular endothelial growth factormediated angiogenesis. J. Biol. Chem. 278, 32100–32106
https://doi.org/10.1074/jbc.M301293200
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G,
Schreck RE, Abrams TJ, Ngai TJ, Lee LB (2003): In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor
targeting vascular endothelial growth factor and plateletderived growth factor receptors. Clin. Cancer Res. 9, 327–337
Mertens S, Noll T, Spahr R, Krützfeldt A, Piper HM (1990): Energetic response of coronary endothelial cells to hypoxia. Am. J.
Physiol. 258, H689–H694
https://doi.org/10.1152/ajpheart.1990.258.3.H689
Moravčík R, Stebelová K, Boháč A, Zeman M (2016): Inhibition of
VEGF mediated post receptor signalling pathways by recently
UN
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
7
Received: October 4, 2018
Final version accepted: November 30, 2018
First published online:
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107